A comprehensive view of Catalent Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Catalent to lay off approximately 130 staff in Bloomington, Indiana, fill-finish plant despite an upcoming takeover by Novo Holdings; the job cuts are part of an ongoing effort to consolidate and reduce costs across its operations
Published: March 22, 2024 by FiercePharma
Novo Holdings acquires contract development and manufacturing organization Catalent for US$16.5B in an all-cash deal; Novo Holdings sells three Catalent manufacturing sites to Novo Nordisk for US$11.0B to boost its diabetes and obesity supply chain
Published: February 08, 2024 by MarketLine
JPMorgan: Novo Nordisk's acquisition of production sites through Catalent is sensible move to help meet weight loss drug demand; production capacity to be increased for injectable Wegovy and Ozempic treatments, allowing Novo to ramp supply for US, world
Published: February 06, 2024 by Proactive Investors
Novo Nordisk to acquire three Catalent fill-finish sites for US$11.0B; the three sites are located in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, and employ more than 3,000 people
Published: February 05, 2024 by GlobeNewswire Europe
Commentary: Weight-loss drugs fuel boom for firms that fill syringes used to administer treatments like Wegovy; companies like WuXi Biologics, Catalent building pre-filled syringe capacities at facilities to serve market that could top US$100B in a decade
Published: October 09, 2023 by Reuters

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count